Log In
BCIQ
Print this Print this
 

ARG301

  Manage Alerts
Collapse Summary General Information
Company arGentis Pharmaceuticals LLC
DescriptionOligopeptide derived from human CII sequence
Molecular Target T cell receptor (TCR)
Mechanism of ActionImmune modulation
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat Rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/16/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today